Home > Full Text Reviews > Drug Class Review: Proton Pump...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cover of Drug Class Review: Proton Pump Inhibitors

Drug Class Review: Proton Pump Inhibitors

Final Report Update 5

Drug Class Reviews

Marian S McDonagh, PharmD, Susan Carson, MPH, and Sujata Thakurta, MPA:HA.

Drug Effectiveness Review Project, Marian McDonagh, PharmD, Principal Investigator, Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director
Portland (OR): Oregon Health & Science University; 2009 May.
Copyright and Permissions

Proton pump inhibitors decrease secretion of gastric acid. They act by blocking the last enzyme in the system that actively transports acid from gastric parietal cells into the gastrointestinal lumen, hydrogen–potassium adenosine triphosphatase, also known as the proton pump. Omeprazole, the first drug in this class, was introduced in 1989. Since then, 4 other proton pump inhibitors have been introduced: lansoprazole (1995), rabeprazole (1999), pantoprazole (2000), and esomeprazole (2001). In 2003 omeprazole became available over-the-counter in the United States. The purpose of this review is to compare the benefits and harms of different PPIs.

Contents

Update 4: May 2006
Update 3: May 2005
Update 2: April 2004
Update 1: April 2003
Original Report: November 2002

The medical literature relating to this topic is scanned periodically. (See http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for description of scanning process). Prior versions of this report can be accessed at the DERP website.

The Drug Effectiveness Review Project, composed of 15 organizations including 14 state Medicaid agencies and the Canadian Agency for Drugs and Technology in Health commissioned and provided funding for this report. These organizations selected the topic of the report and had input into its Key Questions. The content and conclusions of the report were entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

McDonagh MS, Carson S, Thakurta S. Drug class review: Proton pump inhibitors. Update 5. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm.

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

PMID: 21089251

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...